MIRM as reported
Mirum Pharmaceuticals, Inc. reported $618M of revenue over the trailing twelve months, +44% on the year before. 8 reported series are charted on this page, each one as filed.
$618M
Revenue, trailing twelve months · to Q2 2026 · +44% against the twelve months before
- Net Income
- −$860M
Net Income · +1369% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$229M
Free Cash Flow · −2751% year on year · trailing twelve months to Q2 2026
- Op Margin
- −130%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $618M | +44% | Q2 2026 |
| Net Income | −$860M | +1369% | Q2 2026 |
| EPS | −$14.56 | +1103% | Q2 2026 |
| Op Margin | −130% | n/a | Q2 2026 |
| Net Margin | −134% | n/a | Q2 2026 |
| ROE | 1976% | n/a | Q2 2026 |
| ROA | −45% | n/a | Q2 2026 |
| Free Cash Flow | −$229M | −2751% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Mirum Pharmaceuticals, Inc. (MIRM) - Revenue & ProfitRevenue & ProfitMirum Pharmaceuticals, Inc. (MIRM)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com